(Ansuvimab)Biosimilar Reference Antibody-GS40031

货号：GS40031

Ansuvimab is a fully human monoclonal antibody developed for the post-exposure treatment of Ebola virus disease. Derived from a survivor of the 1995 Kikwit Ebola outbreak, it specifically targets a conserved, essential epitope on the Ebola virus glycoprotein (GP). The antibody functions by potently neutralizing the virus, blocking its entry into host cells. In a landmark clinical trial during the 2018-2020 Ebola outbreak in the Democratic Republic of the Congo, ansuvimab (as part of a multi-antibody cocktail) demonstrated a significant survival benefit, leading to its approval by the U.S. FDA and other regulatory bodies. It represents a critical advance in the therapeutic arsenal against this deadly viral hemorrhagic fever.